A5070416385- Genetics, Bioinformatics, and Biomedical Research
- Hepatitis C virus research
- Hepatitis B Virus Studies
- Science, Research, and Medicine
- Biological Research and Disease Studies
- COVID-19 and healthcare impacts
- Thyroid Cancer Diagnosis and Treatment
- Pancreatic and Hepatic Oncology Research
- Cancer Treatment and Pharmacology
- Liver Disease Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Cancer Cells and Metastasis
- PARP inhibition in cancer therapy
- Health Systems, Economic Evaluations, Quality of Life
- Biomedical Ethics and Regulation
- Economic and Financial Impacts of Cancer
- Chemical Reactions and Isotopes
- Cancer Genomics and Diagnostics
- 3D Printing in Biomedical Research
- Gastrointestinal motility and disorders
- Cancer Immunotherapy and Biomarkers
- Organ Transplantation Techniques and Outcomes
- Angiogenesis and VEGF in Cancer
- Neutropenia and Cancer Infections
- Intestinal Malrotation and Obstruction Disorders
PharmaMar (Spain)
2007-2023
LabCorp (United States)
2021-2022
Covance (United States)
2020
Eisai (United Kingdom)
2012-2015
Royal Marsden Hospital
2007-2009
Institute of Cancer Research
2007-2009
Cancer Research UK
2007-2009
Erasmus MC
2009
Hospital de Basurto
1997-2008
Institut Català d'Oncologia
2005-2007
Lenvatinib, an oral inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, fibroblast 1 through 4, platelet-derived receptor α, RET, KIT, showed clinical activity in a phase 2 study involving patients with differentiated thyroid cancer that was refractory to radioiodine (iodine-131).In our randomized, double-blind, multicenter progressive iodine-131, we randomly assigned 261 receive lenvatinib (at daily dose 24 mg per day 28-day cycles) 131 placebo. At the time disease...
in the epidemiology and clinical association of sickle cell disease with malaria, bacterial viral infections (including SARS-CoV-2), suggests that should be included Integrated Management Childhood Illness programme to improve outcomes.Provision for diagnosis treatment incorporated into national health systems programming, an emphasis on delivering services primary care setting.COVID-19 is expected herald a global economic recession might result contraction international funding development...
Summary Three cardinal manifestations of neoplasia, namely inflammation, immune dysfunction, and coagulopathy are also seen in patients with severe SARS-CoV-2 infection, providing a biological rationale for testing selected anticancer drugs their ability to control the symptoms and/or modify course COVID-19.
As a result of the unprecedented challenges imposed by COVID-19 pandemic on enrollment to cancer clinical trials, there has been an urgency identify and incorporate new solutions mitigate these difficulties. The concept decentralized or hybrid trials rapidly gained currency, given that it aims reduce patient burden, increase retention, preserve quality life, while also increasing efficiency trial logistics. Therefore, environment is moving toward remote collection assessment data,...
Abstract A dose-escalation, phase I study evaluated the safety, pharmacokinetics, pharmacogenomics, and efficacy of ES-285, a novel agent isolated from marine mollusc, in adult cancer patients. Patients received 24-hour i.v. infusion ES-285 once every 3 weeks until disease progression or unacceptable toxicity. The starting dose was 4 mg/m2. Dose escalation cohorts at least three patients proceeded according to worst toxicity observed previous cohort. Twenty-eight were treated with 72 courses...
LBA6008 Background: Lenvatinib (LEN) is an oral tyrosine kinase inhibitor of the VEGFR1-3, FGFR1-4, PDGFRβ, RET, and KIT signaling networks. Based on efficacy results phase 2 study patients (pts) with 131 I-refractory differentiated thyroid cancer (RR-DTC), this 3 Study (E7080) in Differentiated Cancer Thyroid (SELECT) was developed. Methods: This randomized, double-blind, placebo (PBO)-controlled enrolled pts RR-DTC documented disease progression within 13 months (mo). Pts were stratified...
The coronavirus disease-2019 (COVID-19) pandemic has had a significant impact on patients with underlying malignancy. In this article, we summarize emerging data related to cancer and COVID-19. Among COVID-19, higher proportion have an diagnosis of than seen in the general population. Also, malignancy are likely be more vulnerable population contracting Mortality is significantly both COVID-19 compared overall COVID-19-positive early months saw decrease screening diagnosis, as well...
Abstract Purpose: Receptor tyrosine kinases c-Met and Ron transduce signals regulating cell migration matrix invasion. This phase I dose-escalation trial tested golvatinib, a highly potent, small-molecule, ATP-competitive inhibitor of multiple members the Eph receptor family plus c-Kit Ron. Experimental Design: Patients with advanced solid tumors received golvatinib orally, once daily, continuously. Using “3+3” design, dosing started at 100 mg escalating to maximum tolerated dose (MTD)...
Case Reports| April 15 2011 Circulating Cancer Cells in Peripheral Blood: A Report Subject Area: Pathology and Cell Biology Nuria Rodríguez-Salas; Rodríguez-Salas From the Departments of Oncology Analytic Hematology, Hospital Universitario La Paz, Madrid, Spain. Search for other works by this author on: This Site PubMed Google Scholar Ana M. Jiménez-Gordo; Jiménez-Gordo Enrique González; González Begoña de las Heras; Heras Pilar Zamora; Zamora Espinosa; Espinosa Mercedes Fernández Castro;...
3030 Background: Golvatinib is a highly potent, small molecule ATP-competitive inhibitor of the c-Met receptor tyrosine kinase and multiple members Eph family as well c-Kit Ron, based on isolated assays. showed preclinical evidence anti-tumor activity. This phase 1 study was performed to determine MTD, safety, PK, PD preliminary activity golvatinib. Methods: Patients (pts) with advanced solid tumors, ECOG PS 0-1, ≥ 18 years (yrs) adequate organ function were eligible. administered orally,...
2513 Background: PM02734 is a chemically synthesized depsipeptide with broad spectrum of activity against solid tumors in vitro (breast, colon, lung, neuroblastoma, prostate, sarcoma and thyroid) vivo melanoma); as well an acceptable non-clinical toxicology profile. Methods: Patients (n=20) metastatic or advanced were enrolled phase I, open-label, dose-escalating study to assess safety, tolerability, pharmacokinetics (PK) infused over 30 min every 21 days (d). The starting dose was 90...
LBA6008 Background: Lenvatinib (LEN) is an oral tyrosine kinase inhibitor of the VEGFR1-3, FGFR1-4, PDGFRβ, RET, and KIT signaling networks. Based on efficacy results phase 2 study patients (pts) with 131I-refractory differentiated thyroid cancer (RR-DTC), this 3 Study (E7080) in Differentiated Cancer Thyroid (SELECT) was developed. Methods: This randomized, double-blind, placebo (PBO)-controlled enrolled pts RR-DTC documented disease progression within 13 months (mo). Pts were stratified by...
Summary Aplastic anaemia complicating hepatitis is a rare but well-documented phenomenon; however in many patients the cause remains unknown. We present 24-year-old man with well-defined community-acquired hepatitis, probably due to G virus (HGV), who developed severe aplastic anaemia. In this case, absence of other agents likely clinical manifestations, and detection HGV RNA at time illness, clearly point agent as being responsible for both Further studies serial serum samples meticulous...
e19531^ Background: E7449 is an orally bioavailable, likely brain penetrable, potent small-molecule inhibitor of poly (ADP-ribose) polymerase (PARP) 1 and PARP 2 with IC50 1.0 1.2 nmol/L respectively. a poor P-gp substrate. Preclinically, potentiates the antitumor activity chemotherapy radiotherapy has as single-agent in BRCA-deficient other tumors. A Phase study single agent underway to determine MTD, safety, PK, PD, preliminary perform exploratory biomarker analysis. Methods: Patients...
2059 Background: KF is a cytotoxic cyclic peptide derived from the mollusc Elysia rufescens. Two prior phase 1 studies assessed hour (h) infusions in 5-day 3-weekly and 1-day weekly schedules. The recommended doses (RD) were 560 650 μg/m2, respectively. dose limiting toxicity (DLT) was reversible transaminase elevation (RTE) which acute, asymptomatic believed to be related Cmax. A prolonged infusion may attenuate this effect allow higher non toxic systemic exposure. Therefore current trial...